System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ghazaleh Tabatabai is an expert in Neurology at Universitätsklinikum Tübingen (Germany). As of October 2026, ScienceLeadR ranks Ghazaleh Tabatabai in the top 1% of experts worldwide for Glioma, Nervous System Neoplasms and Brain Neoplasms. Ghazaleh Tabatabai has authored 409 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 8 of them ongoing. SLR score: 1,680 (community average: 125). How the SLR is computed.

LeadR Profile

Ghazaleh Tabatabai Universitätsklinikum Tübingen Germany
1 680 ScienceLeadR Reputation 1680

Unlock

Register Login
Network Map

Neurology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

University of Tübingen

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 409

Citations

Citations: 13 815 1st author: 37 Last author: 56 Unique author: 3

Main journals

Neuro Oncol 116
J Clin Oncol 21
Neurooncol Adv 13
J Neurooncol 11
Cancer Res 8

Best Journals

J Clin Oncol 9
Nature 5
Ann Oncol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Fanconi anemia pathway disruption drives lomustine sensitivity in glioma.
PMID 42858234 — brain neoplasms, genes, glioma, anemia, neoplasms, lomustine, fanconi anemia, glioblastoma, therapeutics		Neuro Oncol20260
The superior prognostic role of pRB1 over p16 immunohistochemistry as a biomarker in meningiomas.
PMID 42706558 — immunohistochemistry, neoplasms, biomarkers, cyclin-dependent kinases, cyclins, meningioma, multivariate analysis, nervous system diseases		Acta Neuropathol Commun20260
DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression.
PMID 42668313 — catenins, disease progression, dna methylation, meningioma, dna		Nat Commun20260
Age-associated epigenomic heterogeneity in papillary tumors of the pineal region: a multicenter YoungNOA investigation.
PMID 42665813 — epigenomics, neoplasms, nervous system diseases		Acta Neuropathol Commun20260
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
PMID 42547583 — vaccines, astrocytoma, neoplasms		Nat Cancer20262

Clinical Studies 26

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Director: 1

By phase:

Phase 1 6
Phase 1/Phase 2 5
Phase 2 5
Phase 3 5
N/A 4
Phase 2/Phase 3 1

By status:

Completed 13
Recruiting 9
Active not recruiting 3
Terminated 1

By type:

Interventional 23
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 6
multicentricup10 17

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase I II trial of meclofenamate in progressive MGMT methylated glioblastoma under temozolomide second line therapy (MecMeth NOA 24)
2024-511264-89-00 — temozolomide, glioblastoma, therapeutics		Phase 2Recruiting2022
Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)
2023-503938-52-00 — glioblastoma, therapeutics, artificial intelligence		Phase 2Recruiting2024
Non Interventional German Leptomeningeal Disease Register
NCT06146010 — meningeal neoplasms, neoplasms, documentation		N/ARecruiting2024
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
NCT05871021 — vascular endothelial growth factor a, neoplasms, bevacizumab, chemoradiotherapy, glioblastoma, diagnosis, therapeutics		Phase 2Active not recruiting2024
ONC201 in H3 K27M mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562 — radiotherapy, glioma, thalamus, capsules, histones, body weight, therapeutics		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS